Legartis, offering a contract analyzing software for laywers and Xeltis, with its restorative approach in heart valve therapy have made are among the finalists of the 2019 Red Herring Top 100 awards Europe.
The Red Herring award recognizes the most innovating and promising technology companies in Europe. The jury follows a criterion with 20 aspects, as part of the assessment to identify the Top 100 companies. Swiss startups have repeatedly met the requirements and received the label. Also in the recent selection, two startups, Legartis and Xeltis have secured a spot to represent Switzerland.
The legaltech startup, Legartis developed the contract intelligence software based on the latest technologies of Machine Learning, Natural Language Processing and Artificial Intelligence. The Software-as-a-Service solution automates the process of analyzing documents allowing companies and lawyers to identify, classify and understand contracts in seconds. Legartis' technology can be applied throughout the lifecycle of legal documents to simplify the work for everyone handling contracts. Whether used for contract review, due diligence or legal document management, legartis enables lawyers to focus on what matters.
Xeltis, a medtech startup based Zurich, developed the first heart valves and blood vessels enabling the body’s natural restoration of heart valve function through a therapeutic approach called Endogenous Tissue Restoration (ETR). With ETR, the patient’s natural healing system develops tissue that pervades Xeltis’ heart valve, forming a new, natural and fully functional valve within it. As ETR occurs, the body gradually absorbs Xeltis implants. This approach has the potential to overcome the limitations of current artificial heart valves and to improve the lives of hundreds of thousands of patients requiring heart valve replacements while reducing overall healthcare system costs.
(RAN)
0Comments
Please login or sign up to comment.
Commenting guidelines